

1 **Association of polypharmacy and burden of comorbidities on COVID-19**
2 **adverse outcomes in people with type 1 or type 2 diabetes**

3
4 JK Gupta¹, R Ravindrarajah¹, G Tilston¹, W Ollier², DM Ashcroft^{3,4}, **AH Heald**^{5,6}

5 ¹ Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health,
6 University of Manchester, Manchester, UK.

7 ² Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK

8 ³ Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, Medicine and
9 Health, University of Manchester, Manchester, UK.

10 ⁴ NIHR Greater Manchester Patient Safety Research Collaboration (PSRC), University of Manchester,
11 UK

12 ⁵ Department of Diabetes and Endocrinology, Salford Royal NHS Foundation Trust, Salford, UK

13 ⁶ Faculty of Biology, Medicine and Health, University of Manchester, UK

14

15 Corresponding author: Adrian.Heald@nca.nhs.uk

16

17 **RUNNING TITLE:** Diabetes and polypharmacy adverse COVID-19 outcome

18

19 **Abstract**

20 Aim: To investigate whether polypharmacy and comorbidities conveyed more risk of adverse health
21 outcomes following COVID-19 infection in people with type 1 diabetes (T1DM) or type 2 diabetes
22 (T2DM).

23 Materials and methods: The Greater Manchester Care Record (GMCR) is an integrated database of
24 electronic health records containing data collected from 433 general practices in Greater
25 Manchester. Baseline demographic information (age, BMI, gender, ethnicity, smoking status,

26 deprivation index), hospital admission or death within 28 days of infection were extracted for adults
27 (18+) diagnosed with either T1DM or T2DM.

28 Results: For T2DM, 16 to 20 medications ($p=0.005$; OR [95% CI]=2.375 [1.306 to 4.319]) and > 20
29 medications ($p<0.001$; OR [95% CI]=3.141 [1.755 to 5.621]) were associated with increased risk of
30 death following COVID-19 infection. Increased risk of hospital admissions in T2DM individuals was
31 associated with 11 to 15 medications ($p=0.013$; OR [95% CI]=1.341 [1.063 to 1.692]) and above. This
32 was independent of comorbidities, metabolic and demographic factors. For T1DM there was no
33 association of polypharmacy with hospital admission. Respiratory, cardiovascular/cerebrovascular
34 and gastrointestinal conditions were associated with increased risk of hospital admissions and
35 deaths in T2DM ($p<0.001$).

36 Conclusion: We have shown in T2DM an independent association of multiple medications taken
37 from 11 upwards with adverse health consequences following COVID-19 infection. We also found
38 that individuals with diabetes develop comorbidities that were common across both T1DM and
39 T2DM. This study has laid the foundation for future investigations into the way that complex
40 pharmacological interactions may influence clinical outcomes in people with T2DM.

41

42 **Keywords:** polypharmacy; comorbidity; electronic health records; COVID-19

43

44 Introduction

45 Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 is the pathogenic coronavirus
46 that led to the 2020 pandemic. COVID-19 infections can lead to adverse outcomes, such as hospital
47 admission or death, the risk of which are increased further for individuals diagnosed with either type
48 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM)^{1,2}. Increased risk of adverse health
49 outcomes following COVID-19 infection have also been linked to other underlying medical
50 conditions, which has raised concerns for chronic disease care³⁻⁷. It has been showed that socially
51 marginalised and psychiatrically vulnerable individuals are at higher risk of severe health outcomes

52 following COVID-19 infection ⁸. McQueenie et al. (2020) investigated the UK Biobank data to
53 determine the association between multi-morbidity (including polypharmacy as a proxy) and COVID-
54 19 infection risk ⁹. McQueenie et al. (2020) reported that individuals diagnosed with ≥ 2
55 cardiometabolic conditions and increasing polypharmacy were associated with increased the risk of
56 COVID-19 infection ⁹.

57 Previous studies of COVID-19 in individuals with T1DM and T2DM (in the Greater Manchester (GM)
58 area) have shown that the prescribing of certain medications influenced the likelihood of
59 hospitalisation or death following COVID-19 infection ^{10,11}. Many individuals in this population are
60 often prescribed, and are taking, multiple medications as they live with other long-term conditions.

61 The definition of 'polypharmacy' has been shown to widely vary in the published literature ¹². In
62 addition to this term, Masnoon et al. (2017) summarised that the terms minor, moderate and major
63 polypharmacy were used in literature to describe when between 2 to 11 or more medications are
64 consumed. The most commonly reported number of medications across these 'polypharmacy' terms
65 was greater than or equal to 5, as identified in the review ¹².

66 It is widely accepted that the higher the number of medications prescribed and taken by an
67 individual, the higher the risk of poor health outcomes. Recent reviews have reported a high
68 prevalence of polypharmacy in older people diagnosed with diabetes and an association with several
69 health-related outcomes, including falls, syncope, hospitalization, and death, as well as highlighting
70 the need to reduce inappropriate prescribing ¹³⁻¹⁵. Several studies have also investigated the
71 relationship between polypharmacy and severe COVID-19 health outcomes ^{16,17}. However, there is
72 little understanding of how polypharmacy in people with diabetes might affect their risk of severe
73 health outcome post COVID-19 infection, other than the public health burden and impact of adverse
74 drug-drug interactions in individuals ¹⁸.

75 Electronic health records (EHR) emerged as a useful tool for public health and COVID-19 research, as
76 described by Madhavan et al. (2021) and Casey et al. (2016) ^{19,20}. It is also useful for improving health
77 service for example by identifying and understanding health inequalities ^{21,22}.

78 To date, there are no studies that explore the associations between both polypharmacy and
79 comorbidity with adverse health outcomes, such as hospital admission or death, post first infection
80 of COVID-19 specifically in individuals with diabetes. This retrospective cohort study aimed to
81 investigate whether polypharmacy independent of comorbidity conveys greater risk of adverse
82 outcomes in people with diabetes when testing positive for COVID-19 infection in UK EHR data.

83

84 **Materials and methods**

85 **Cohort data source**

86 The Greater Manchester Care Record (GMCR) is an integrated database of primary care, secondary
87 care and mental health trusts from across GM ([https://gmwearebettertogether.com/research-and-](https://gmwearebettertogether.com/research-and-planning/)
88 [planning/](https://gmwearebettertogether.com/research-and-planning/)) for analyses covering a population of approximately 3 million people. Health and care
89 data were collected from 433 of 435 (99.5%) general practices in GM. Data were de-identified at
90 source and were extracted from the GMCR database. This was a retrospective cohort study with the
91 period of follow-up 2020 to 2022 in relation to the main impact period of the COVID-19 pandemic.
92 The inclusion criteria for this study were defined as individuals that are registered with a GM GP
93 practice and with a diagnosis of T1DM or T2DM and age 18 or above. Individuals with a positive test
94 for COVID-19 close to January 2020 were included in this study. The study included all people
95 diagnosed with diabetes and with data available in the GMCR in January 2020. No power calculation
96 was performed as we included all people with that diagnosis.

97

98 **Variables and data cleaning**

99 Baseline demographic information (age, BMI, gender, ethnicity, smoking status, deprivation index),
100 hospital admission or death within 28 days of infection were extracted for adults (18+) diagnosed
101 with either T1DM or T2DM (the codes applied are summarised in Appendix 1). Other rare forms of
102 diabetes were not included.

103 Hospital admissions were recorded within 4 weeks after, or 2 weeks before a positive COVID-19 test
104 (between Jan 2020 to May 2022). The exposure was defined as prescribed medications, which were
105 recorded in the EHRs and mapped to the corresponding BNF (British National Formulary) chapters.
106 For this study, medications were considered at a single point in time, the month closest to first
107 COVID-19 infection date (January 2020 onwards). The BNF groups were not mutually exclusive,
108 therefore medications that are grouped under more than one chapter were counted. History of
109 comorbidity was collected before March 2020.

110 Individuals who were not assigned a gender were excluded. A total of 410 individuals having a code
111 for both T1DM and T2DM were excluded. The study confounders were determined by literature
112 review. In studies using real world data analysis, a number of factors were not covered in the coded
113 data such as household makeup and employment. Links to the codes used for diabetes can be found
114 in the supplementary information. Data were checked for extreme outliers or inconsistent values
115 and removed as appropriate.

116 **Ethics**

117 This project was reviewed, and ethical approval for COVID-19 research was overseen by Health
118 Innovation Manchester and granted by the Greater Manchester Care Record (GMCRC) review board
119 (ref: IDCR-RQ-046). This research was performed with anonymised data, in line with the Health
120 Research Authority's Governance arrangements for research ethics committees.

121 **Statistical methods**

122 Multivariable logistic regression analyses using a forward stepwise approach were performed on the
123 T1DM and T2DM individuals, measuring exposure to number of medications and comorbidities, with
124 either hospital admission or death after COVID-19 infection (within 28 days of COVID-19 diagnosis)
125 as the outcome. The models were adjusted for age, BMI, ethnicity, smoking status, IMD, eGFR <60
126 ml/min/1.73m², cholesterol, HBA1C and blood pressure. Analyses were performed in STATA v17. This
127 manuscript follows the reporting recommendation of RECORD-PE ²³.

128

129 Results

130 The study cohort included patients diagnosed as T1DM and T2DM separately. Across the Greater
 131 Manchester Region a total of 145,907 individuals were diagnosed with T2DM and 9,705 were
 132 diagnosed with T1DM (Table 1; Table 2). The number of deaths in T1DM were too low (n=30) for
 133 further statistical analyses to explore the association with mortality.

134

135 **Table 1. Baseline demographics of individual diagnosed with Type 1 diabetes (T1DM) or Type 2**
 136 **diabetes (T2DM).**

	Type 1 Diabetes	Type 2 Diabetes
	<i>N=9,705</i>	<i>N=145,907</i>
Age (years)	47.3±16.8	65.8±13.8
BMI (kg/m ²)	27.7±7.0	31.0±7.7
Sex		
Female	4143 (42.7)	65922 (45.2)
Male	5562 (57.3)	79985 (54.8)
Smoking status		
Non-smoker	3967 (40.9)	51823 (35.5)
Current smoker	1804 (18.6)	20906 (14.3)
Ex-smoker	3765 (38.8)	71519 (49.0)
Unknown/missing	169 (1.7)	1659 (1.1)
Ethnicity		
White	8020 (82.6)	102051 (69.9)
Asian	565 (5.8)	25359 (17.4)
Black	221 (2.3)	5176 (3.6)
Mixed	107 (1.1)	1528 (1.1)
Other	379 (3.9)	6184 (4.2)
Missing/refused	413 (4.3)	5609 (3.8)
Deprivation index/Townsend quintile (IMD)		
1 (least deprived)	1182 (12.2)	13471 (9.2)
2	1451 (15.0)	19080 (13.1)
3	1395 (14.4)	18017 (12.4)
4	1984 (20.4)	28863 (19.8)
5 (most deprived)	3680 (37.9)	66426 (45.5)
Missing	13 (0.1)	50 (0.03)
Total number of medications prescribed *		
0	543 (5.60)	13359 (9.16)
1 to 5	5822 (59.99)	51999 (35.64)
6 to 10	1879 (19.36)	38533 (26.41)
11 to 15	744 (7.67)	21433 (14.69)
16 to 20	348 (3.59)	9880 (6.77)
> 20	369 (3.80)	10703 (7.34)
Systolic blood pressure (mm Hg) †	127.1±15.2	131.1±14.5

Diastolic blood pressure (mm Hg) †	74.8±9.8	75.9±9.6
HBA1C (mmol/mol) †	69.3±20.3	56.8±17.0
eGFR (mL/min/1.73 m ²) < 60 ‡	907 (9.4)	25851 (17.7)
eGFR (mL/min/1.73 m ²) †	81.0±15.5	75.4±17.2
Cholesterol (mmol/mol) †	4.5±1.1	4.3±1.1
LDL (mmol/L) †	2.4±0.9	2.2±0.9
HDL (mmol/L) †	1.5±0.5	1.2±0.4
Diabetes duration (years)	20.6±14.3	10.4±7.45
Vaccination status: (defined prior to/around the time of first infection)		
Yes	8816 (90.8)	135141 (92.6)
No	889 (9.2)	10766 (7.4)
Prescribed medications: *		
Metformin	1015 (10.5)	72084 (49.4)
SGLT2 •	163 (1.7)	16134 (11.1)
Insulin	6854 (70.6)	12149 (8.3)
Arb/ACE inhibitors	1759 (18.1)	44127 (30.2)
Antiplatelet (clopidogrel/aspirin)	1177 (12.1)	31403 (21.5)
Angiotensin receptor blockers	710 (7.3)	20168 (13.8)
Sulphonylureas	98 (1.0)	22011 (15.1)
GLP1 receptor agonists	79 (0.8)	4475 (3.1)
Alogliptin	36 (0.4)	10196 (7.0)
Linagliptin	37 (0.4)	5388 (3.7)
Saxagliptin	< 10 (0)	944 (0.7)
Sitagliptin	29 (0.3)	6570 (4.5)
Vildagliptin	< 10 (0)	396 (0.27)
Admission to hospital (within 28 days of infection)	146(1.5)	2107 (1.4)
Length of stay in hospital (days)	4.5±8.3	7.1±11.9
Deaths (within 28 days of confirmed infection)	30 (0.3)	885 (0.6)

137 Categorical variables presented as N (%) and continuous variables as mean (±SD)

138 Townsend index: 1 denotes the least deprived and 5 the most deprived.

139 * Medications prescribed close to January 2020.

140 † Closest point before first COVID-19 +ve test

141 ‡ Estimated glomerular filtration rate

142 • Sodium glucose co-transporter 2 inhibitor (SGLT2i) or a glucagon-like peptide 1 (GLP-1) agonist.

143

144 A varying number of multiple medications were prescribed to individuals with T1DM or T2DM (Table
 145 1). A large proportion of individuals were prescribed between 1 to 5 medications; the distribution of
 146 number of medications prescribed and BNF chapters can be seen in Figure S1 and Figure S2. In
 147 T2DM, after endocrine and cardiovascular medications, the largest number of multiple prescriptions
 148 were from the gastrointestinal (GI) BNF chapter.

149 Common comorbidities were grouped into broader categories (see Supplementary Information

150 Table S1) and counts were collated for T1DM and T2DM. The top six modal comorbidity groups

151 identified in T2DM were mental health conditions, hypertension, gastrointestinal or liver disease,
152 pain, respiratory conditions (or sinus-related) and cardiovascular/cerebrovascular conditions (Table
153 2). Of the individuals diagnosed with T2DM, 69.9% were diagnosed with hypertension and 44.9%
154 with mental health conditions (Table 2). The same six comorbidity groups were also identified in the
155 individuals with T1DM (Table S2).

156

157 **Table 2. Prevalence of comorbidity groups in individuals diagnosed with T2DM. The top 6 groups**
158 **are shown in italics.**

Morbidity group	N	%
<i>Hypertension</i>	101995	69.9
<i>GI/liver disease</i>	82193	56.3
<i>Mental health disorder</i>	65487	44.9
<i>Pain</i>	60237	41.3
<i>Cardiovascular/cerebrovascular</i>	48213	33.0
<i>Respiratory/sinus</i>	41653	28.6
Sensory	34541	23.7
Skin/connective tissue disorder	28459	19.5
Chronic kidney disease	27931	19.1
Neurological disorders	22795	15.6
Thyroid disorders	14476	9.9
Prostate diseases	9276	6.4
Alcohol substance abuse	9108	6.2
Cancer	7892	5.4
Dementia	6498	4.5
Glaucoma	6262	4.3
Learning disability	1016	0.7

159

160 **Logistic Regression Analysis**

161 Odds ratios (95% confidence intervals) of the univariate regression are reported in the individuals
162 with T1DM and T2DM respectively.

163 **T1DM**

164 An increased risk of adverse outcomes post-infection was observed for individuals with T1DM and
165 GI/liver disorders ($p < 0.001$; OR [95% CI] = 3.452 [2.118 to 5.625]) and pain associated conditions
166 ($p = 0.04$; OR [95% CI] = 1.556 [1.021 to 2.372]) (Table 3). Age was determined as slightly protective of
167 hospital admission following COVID-19 diagnosis ($p < 0.001$; OR [95% CI] = 0.964 [0.949 to 0.980]).

168 Other significant variables included eGFR < 60 (p<0.001; OR [95% CI] = 2.794 [1.746 to 4.47]). There
 169 was no association with polypharmacy.

170

171 **Table 3. Logistic regression analyses of hospital admission following COVID-19 diagnosis in**
 172 **individuals with T1DM.**

Variable	OR (95% CI)	p value
Age	0.964 (0.949 to 0.980)	< 0.001
Sex	0.792 (0.537 to 1.167)	0.239
BMI	0.989 (0.960 to 1.02)	0.485
Ethnicity		
Asian	0.919 (0.431 to 1.956)	0.826
Black	0.388 (0.052 to 2.882)	0.355
Mixed	1.889 (0.444 to 8.04)	0.390
Other	0.447 (0.108 to 1.852)	0.267
Unknown	0.250 (0.035 to 1.809)	0.170
Smoking status		
Current smoker	0.856 (0.487 to 1.507)	0.590
Ex- smoker	1.022 (0.665 to 1.571)	0.921
Unknown/missing	1.237 (0.285 to 5.359)	0.777
IMD		
2	0.865 (0.404 to 1.851)	0.708
3	0.65 (0.291 to 1.452)	0.294
4	0.999 (0.501 to 1.992)	0.998
5 (most deprived)	0.843 (0.441 to 1.61)	0.604
eGFR<60	2.794 (1.746 to 4.47)	< 0.001
Cholesterol	0.925 (0.780 to 1.097)	0.369
HBA1C	1.002 (0.993 to 1.011)	0.681
Systolic BP	0.998 (0.984 to 1.012)	0.788
Diastolic BP	1.018 (0.996 to 1.041)	0.105
Comorbidity groups		
Mental health disorder	0.690 (0.463 to 1.028)	0.068
Hypertension	1.179 (0.746 to 1.865)	0.480
GI/liver disorder	3.452 (2.118 to 5.625)	< 0.001
Pain	1.556 (1.021 to 2.372)	0.040
Respiratory/sinus conditions	0.986 (0.650 to 1.496)	0.948
Cardiovascular/cerebrovascular	1.327 (0.814 to 2.162)	0.257
Total number of medications		
1 to 5	1.001 (0.235 to 4.271)	0.999
6 to 10	2.139 (0.488 to 9.381)	0.313
11 to 15	2.496 (0.539 to 11.554)	0.242
16 to 20	3.577 (0.738 to 17.329)	0.113
> 20	2.158 (0.424 to 10.989)	0.355

173 Odds ratios and 95% confidence intervals from the logistic regression model of hospital admission
 174 post COVID-19 diagnosis.

175

176 **T2DM**

177 In individuals with T2DM, an increased number of medications, from 11 upwards was associated
178 with increased risk of hospital admission following COVID-19 infection (Table 4). Individuals
179 diagnosed with co-morbidities in the following morbidity groups had an increased likelihood of
180 hospital admission: mental health disorders ($p=0.003$; OR [95% CI] = 1.167 [1.054 to 1.292]); Gastro-
181 intestinal/liver disorders ($p<0.001$; OR [95% CI] = 1.977 [1.741 to 2.245]); pain ($p<0.001$; OR [95% CI]
182 = 1.407 [1.265 to 1.564]); respiratory/sinus conditions ($p<0.001$; OR [95% CI] = 1.235 [1.115 to
183 1.369]) and cardiovascular/cerebrovascular conditions ($p<0.001$; OR [95% CI] = 1.443 [1.292 to
184 1.612]). People with T2DM and eGFR level <60 ($p<0.001$; OR [95% CI] = 1.431 [1.268 to 1.614]) also
185 had an increased risk of hospital admission, similarly HBA1C levels ($p=0.009$; OR [95% CI] = 1.004
186 [1.001 to 1.006]) were also at increased risk (Table 4).

187 Males were more likely to be admitted to hospital after infection with COVID-19 ($p<0.001$; OR [95%
188 CI] = 1.312 [1.181 to 1.457]). High BMI was associated with a higher likelihood of adverse outcomes
189 (hospitalisation & mortality) from COVID-19 ($p=0.002$; OR [95% CI] = 1.011 [1.004 to 1.018]). Age was
190 protective of hospital admission; however the odds ratio was only slightly less than 1 ($p=0.009$; OR
191 [95% CI] = 0.993 [0.988 to 0.998]). Individuals of Asian ($p=0.006$; OR [95% CI] = 1.213 [1.058 to 1.39])
192 or Black ($p=0.003$; OR [95% CI] = 1.441 [1.129 to 1.838]) ethnicities were also more likely to be
193 admitted to hospital following infection (Table 4).

194 Individuals who identified as 'current smokers' were not identified as being at increased risk
195 ($p<0.001$; OR [95% CI] = 0.507 [0.419 to 0.614]). However, individuals who lived in areas with higher
196 social disadvantage were more likely to be admitted to hospital - IMD quintiles 4 and 5 ($p=0.02$; OR
197 [95% CI] = 1.278 [1.039 to 1.572]; $p=0.033$; OR [95% CI] = 1.236 [1.017 to 1.503]) (Table 4).

198

199 **Table 4. Logistic regression analyses of hospital admission within 28 days of COVID-19 diagnosis in**
200 **individuals with T2DM.**

Variable	OR (95% CI)	p value
----------	-------------	---------

Age	0.993 (0.988 to 0.998)	0.009
Sex	1.312 (1.181 to 1.457)	< 0.001
BMI	1.011 (1.004 to 1.018)	0.002
Ethnicity		
Asian	1.213 (1.058 to 1.39)	0.006
Black	1.441 (1.129 to 1.838)	0.003
Mixed	1.059 (0.632 to 1.774)	0.827
Other	0.96 (0.744 to 1.239)	0.754
Unknown	0.947 (0.701 to 1.28)	0.725
Smoking status		
Current smoker	0.507 (0.419 to 0.614)	< 0.001
Ex- smoker	0.998 (0.894 to 1.115)	0.977
Unknown/missing	0.856 (0.525 to 1.396)	0.533
IMD		
2	1.07 (0.851 to 1.345)	0.562
3	1.091 (0.868 to 1.373)	0.454
4	1.278 (1.039 to 1.572)	0.020
5 (most deprived)	1.236 (1.017 to 1.503)	0.033
eGFR<60	1.431 (1.268 to 1.614)	< 0.001
Cholesterol	1.021 (0.976 to 1.068)	0.369
HBA1C	1.004 (1.001 to 1.006)	0.009
Systolic BP	1.001 (0.997 to 1.005)	0.709
Diastolic BP	1.002 (0.996 to 1.008)	0.470
Comorbidity groups		
Mental health disorder	1.167 (1.054 to 1.292)	0.003
Hypertension	1.074 (0.946 to 1.219)	0.272
GI/liver disorder	1.977 (1.741 to 2.245)	< 0.001
Pain	1.407 (1.265 to 1.564)	< 0.001
Respiratory/sinus conditions	1.235 (1.115 to 1.369)	< 0.001
Cardiovascular/cerebrovascular	1.443 (1.292 to 1.612)	< 0.001
Total number of medications		
1 to 5	1.123 (0.901 to 1.401)	0.302
6 to 10	1.108 (0.886 to 1.387)	0.370
11 to 15	1.341 (1.063 to 1.692)	0.013
16 to 20	1.45 (1.124 to 1.87)	0.004
> 20	1.53 (1.191 to 1.966)	0.001

201 Odds ratios and 95% confidence intervals from the logistic regression model of hospital admission
 202 post COVID-19 diagnosis.

203

204 In individuals with T2DM, the number of deaths was 885 (0.6% of the total number of individuals
 205 diagnosed with T2DM) (Table 1). An increased number of medications, from 16 to 20 to > 20 was
 206 associated with increased risk of death following COVID-19 infection (p=0.005; OR [95% CI] = 2.375
 207 [1.306 to 4.319] and p<0.001; OR [95% CI] = 3.141 [1.755 to 5.621] respectively) (Table 5).

208 People diagnosed with the following long-term conditions were at higher risk of death post-
 209 infection: mental health disorders ($p < 0.001$; OR [95% CI] = 1.544 [1.219 to 1.954]); respiratory/sinus
 210 conditions ($p < 0.001$; OR [95% CI] = 1.573 [1.245 to 1.988]) or cardiovascular/cerebrovascular
 211 conditions ($p < 0.001$; OR [95% CI] = 1.691 [1.297 to 2.203]). A protective effect was observed for
 212 individuals living with GI/liver disorder ($p < 0.001$; OR [95% CI] = 0.519 [0.404 to 0.666]) or pain
 213 ($p < 0.001$; OR [95% CI] = 0.513 [0.4 to 0.657]) (Table 5).

214 As with hospital admission, the risk of death increased in males and with high BMI ($p = 0.017$; OR
 215 [95% CI] = 1.35 [1.054 to 1.728] and $p = 0.004$; OR [95% CI] = 1.021 [1.007 to 1.036] respectively). Age
 216 was associated with an increased risk of mortality post COVID-19 infection ($p < 0.001$; OR [95% CI] =
 217 1.092 [1.078 to 1.107]) (Table 5).

218 Individuals with T2DM and living in the most deprived regions (IMD 5) were at higher risk of death
 219 following COVID-19 infection ($p = 0.021$; OR [95% CI] = 1.684 [1.081 to 2.623]) or if their eGFR level
 220 measure was < 60 ($p = 0.011$; OR [95% CI] = 1.382 [1.078 to 1.771]) (Table 5).

221

222 **Table 5. Logistic regression analyses of deaths within 28 days of COVID-19 diagnosis in individuals**
 223 **with T2DM.**

Variable	OR (95% CI)	p value
Age	1.092 (1.078 to 1.107)	< 0.001
Sex	1.35 (1.054 to 1.728)	0.017
BMI	1.021 (1.007 to 1.036)	0.004
Ethnicity		
Asian	0.719 (0.46 to 1.123)	0.147
Black	0.666 (0.272 to 1.631)	0.374
Mixed	1.418 (0.447 to 4.5)	0.553
Other	0.696 (0.357 to 1.36)	0.289
Smoking status		
Unknown	1.259 (0.717 to 2.212)	0.423
Current smoker	1.015 (0.665 to 1.549)	0.945
Ex- smoker	0.945 (0.724 to 1.234)	0.677
Unknown/missing	Omitted	
IMD		
2	1.444 (0.88 to 2.37)	0.146
3	1.181 (0.7 to 1.993)	0.534
4	1.481 (0.921 to 2.381)	0.105
5 (most deprived)	1.684 (1.081 to 2.623)	0.021
eGFR < 60	1.382 (1.078 to 1.771)	0.011

Cholesterol	1.084 (0.973 to 1.207)	0.145
HBA1C	1 (0.992 to 1.008)	0.967
Systolic BP	0.993 (0.985 to 1.002)	0.122
Diastolic BP	1.001 (0.987 to 1.015)	0.906
Comorbidity groups		
Mental health disorder	1.544 (1.219 to 1.954)	< 0.001
Hypertension	0.794 (0.574 to 1.099)	0.164
GI/liver disorder	0.519 (0.404 to 0.666)	< 0.001
Pain	0.513 (0.4 to 0.657)	< 0.001
Respiratory/sinus conditions	1.573 (1.245 to 1.988)	< 0.001
Cardiovascular/cerebrovascular	1.691 (1.297 to 2.203)	< 0.001
Total number of medications		
1 to 5	0.583 (0.32 to 1.06)	0.077
6 to 10	0.945 (0.536 to 1.665)	0.844
11 to 15	1.429 (0.802 to 2.545)	0.226
16 to 20	2.375 (1.306 to 4.319)	0.005
> 20	3.141 (1.755 to 5.621)	< 0.001

224 Odds ratios and 95% confidence intervals from the logistic regression model of mortality post COVID-
225 19 diagnosis.

226

227 Discussion

228 This study uniquely explored the relationship between number of medications and adverse outcome
229 from COVID-19 infection in individuals diagnosed with diabetes in the Greater Manchester
230 population and is therefore distinct from our previous published studies in this area^{10,11}. We found
231 that the number of medications prescribed to an individual was associated with an increased risk of
232 severe outcome from COVID-19 infection, particularly in people living with T2DM (Table 4; Table 5).
233 Given the large proportion of individuals diagnosed with comorbidities, it was not unexpected that
234 many of these individuals were prescribed multiple medications (Figure S1; Figure S2). However, the
235 effect of multiple medications was independent of the presence of the most common comorbidities.
236 Polypharmacy, independent of other factors including major multimorbidity, was associated with an
237 increased likelihood of hospital admission in people with T1DM and of hospitalisation and death in
238 T2DM following COVID-19 infection. This has not been specifically reported previously, although it
239 was described in older individuals²⁴. This is of relevance to the consequences following any serious
240 viral infection in people with diabetes, while also highlighting the importance of regular medicine

241 reviews in everyone with diabetes, where there may be an opportunity to reduce the prescribed
242 medications ²⁵.

243 The mean ages of individuals diagnosed with T1DM or T2DM are similar to the mean ages of a
244 Swedish cohort investigated by ¹. In our study we also identified several co-morbidities that
245 increased the risk of adverse health outcome post COVID-19 infection. Similar co-morbidities were
246 identified for both individuals with T1DM and T2DM. Notably, we also identified that there were a
247 large proportion of diagnoses of mental health conditions in people with T2DM (Table 2), though the
248 highest number of diagnoses was observed in people with T1DM (Table S2). The relation between
249 physical health conditions and poor mental health is an area that is not fully understood. In addition
250 to this, the impact of polypharmacy is unknown.

251 The risk of hospital admission in current smokers was less than non-smokers. The reason for this
252 may be that people with multiple health issues and who are smokers may have stopped smoking in
253 the weeks or months before a COVID-19 infection and therefore not be deemed as a smoker at the
254 time of the COVID-19 infection.

255 Over-prescribing is an issue in the current healthcare system. Medication is routinely recorded,
256 therefore in clinical practice there is the potential to flag the number of medications prescribed to
257 clinicians to monitor. Thereby the number of prescriptions given to vulnerable individuals could be
258 limited as appropriate and effective for the individual, though this does require both routine
259 monitoring and structured reviews of the medications that people are taking. The UK healthcare
260 system looks to improve the management of prescriptions, and the removal of unnecessary
261 medications is key to reducing the burden of polypharmacy ^{26,27}.

262 One of the limitations of this study is that a measure of 'frailty' was not included ²⁸. However, a
263 count of comorbidities is included which could possibly be used as a proxy for frailty. As the data
264 from this study originated from electronic health records, it is also subject to the limitations of how
265 information is coded when originally entered into the systems, such as missing data. Only 70% of
266 individuals with T1DM were recorded with a prescription of insulin (Table 1), this could be due to

267 lack of recording or unclear diagnosis, which highlights another issue with routinely collected data.
268 Another issue is that medications recorded in the health care records are not true reflections of
269 medications that are concordant with the choices of the individual²⁹. A study in the United States
270 demonstrated that EHR-related medication errors can occur at different stages including at ordering,
271 preparation, dispensing, administering or monitoring stage, these can ultimately affect the data in
272 EHRs³⁰. Inaccuracies of coding are inherent in any project that relies on primary coded data.
273 Nevertheless, the large number of people included in the study means that such inaccuracies are
274 unlikely materially to influence the results. Furthermore, medications can also be counted in more
275 than one BNF chapter, making it difficult to determine unique counts. As this data was from one
276 region in the UK, it is difficult to generalise to the rest of the population. Finally in studies using real
277 world data analysis, there will be a number of factors that are not covered in the coded data such as
278 household makeup and employment.

279 Future work would include investigating the modal medications prescribed in this cohort and explore
280 possible drug-drug interactions between medications that could contribute to increasing the risk of
281 adverse outcome post COVID-19 infection. The burden of mental health conditions on people with
282 diabetes and how to effectively manage multiple long-term conditions, could also be explored. The
283 knowledge gained would be useful for future pandemics and better prepare our healthcare system.

284 In conclusion, we have identified that multiple medications were prescribed to many people living
285 with diabetes and that this was associated with a higher risk of adverse health outcome following
286 COVID-19 infection. We also found that individuals with diabetes also developed comorbidities that
287 were common across both Type 1 and 2 diabetes. Our analysis confirmed the impact of higher levels
288 of deprivation on increasing a person's risk of adverse outcome post COVID-19 infection. This study
289 has laid the foundation for future investigations into the increased and complex treatments people
290 living with diabetes who develop other clinical complications.

291

292 Acknowledgements

293 This work was supported by the Turing-Manchester Feasibility Project Funding. The authors
294 recognise the Greater Manchester Care Record (a partnership of Greater Manchester Health and
295 Social Care Partnership, Health Innovation Manchester and Graphnet Health, on behalf of Greater
296 Manchester localities) in the provision of data required to undertake this work. This work uses data
297 provided by patients and collected by the NHS as part of their care and support. GT was funded by
298 the NIHR Manchester Biomedical Research Centre (NIHR203308) for this work. DMA is supported by
299 the NIHR Greater Manchester Patient Safety Research Collaboration (PSRC). The views expressed are
300 those of the authors and not necessarily those of the NIHR or the Department of Health and Social
301 Care.

302 Author contributions

303 RR performed the data cleaning and data analyses. JG, WO and AHH conceived the study. JG
304 prepared the figures and the manuscript. GT extracted the original dataset. DM WO and AHH
305 contributed to all sections of the paper and DM provided expert input from a pharmacological
306 perspective. All authors were involved in designing the study, interpreting results and the reviewing
307 and editing of the manuscript.

308 Conflicts of interest

309 Authors declare no conflict of interest.

310 Data availability statement

311 The datasets generated during and analysed during the current study are not publicly available as all
312 data access is subject to review by Health Innovation Manchester.

313 Supplementary Materials

314 Links to the clinical codes applied for diabetes diagnoses can be found in the 'methods' section of
315 the supplementary material file. Figure S1: distribution of medications prescribed in T1DM

316 individuals. Figure S2: distribution of medications prescribed in T1DM individuals. Table S1:
317 breakdown of comorbidity groups. Table S2: Prevalence of comorbidities groups in T1DM.

318 Preprint

319 A preprint has previously been published [31].

320 References

- 321 1. Rawshani A, Kjölhede EA, Rawshani A, et al. Severe COVID-19 in people with type 1 and type 2
322 diabetes in Sweden: A nationwide retrospective cohort study. *The Lancet Regional Health -*
323 *Europe*. 2021;4:100105. doi:10.1016/j.lanepe.2021.100105
- 324 2. Izzì-Engbeaya C, Distaso W, Amin A, et al. Adverse outcomes in COVID-19 and diabetes: a
325 retrospective cohort study from three London teaching hospitals. *BMJ Open Diabetes Res Care*.
326 2021;9(1):e001858. doi:10.1136/bmjdr-2020-001858
- 327 3. Kone AP, Martin L, Scharf D, et al. The impact of multimorbidity on severe COVID-19 outcomes
328 in community and congregate settings. *Dialogues in Health*. 2023;2:100128.
329 doi:10.1016/j.dialog.2023.100128
- 330 4. Li Y, Ashcroft T, Chung A, et al. Risk factors for poor outcomes in hospitalised COVID-19 patients:
331 A systematic review and meta-analysis. *J Glob Health*. 11:10001. doi:10.7189/jogh.11.10001
- 332 5. Fekadu G, Bekele F, Tolossa T, et al. Impact of COVID-19 pandemic on chronic diseases care
333 follow-up and current perspectives in low resource settings: a narrative review. *Int J Physiol*
334 *Pathophysiol Pharmacol*. 2021;13(3):86-93.
- 335 6. Danhieux K, Buffel V, Pairon A, et al. The impact of COVID-19 on chronic care according to
336 providers: a qualitative study among primary care practices in Belgium. *BMC Family Practice*.
337 2020;21(1):255. doi:10.1186/s12875-020-01326-3
- 338 7. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic
339 literature review and meta-analysis. *Journal of Infection*. 2020;81(2):e16-e25.
340 doi:10.1016/j.jinf.2020.04.021
- 341 8. Nilsson SF, Laursen TM, Osler M, et al. Adverse SARS-CoV-2-associated outcomes among people
342 experiencing social marginalisation and psychiatric vulnerability: A population-based cohort
343 study among 4,4 million people. *The Lancet Regional Health - Europe*. 2022;20:100421.
344 doi:10.1016/j.lanepe.2022.100421
- 345 9. McQueenie R, Foster HME, Jani BD, et al. Multimorbidity, polypharmacy, and COVID-19 infection
346 within the UK Biobank cohort. *PLOS ONE*. 2020;15(8):e0238091.
347 doi:10.1371/journal.pone.0238091
- 348 10. Heald AH, Jenkins DA, Williams R, et al. The Risk Factors Potentially Influencing Hospital
349 Admission in People with Diabetes, Following SARS-CoV-2 Infection: A Population-Level Analysis.
350 *Diabetes Ther*. 2022;13(5):1007-1021. doi:10.1007/s13300-022-01230-2

- 351 11. Heald AH, Jenkins DA, Williams R, et al. Mortality in People with Type 2 Diabetes Following
352 SARS-CoV-2 Infection: A Population Level Analysis of Potential Risk Factors. *Diabetes Ther.*
353 2022;13(5):1037-1051. doi:10.1007/s13300-022-01259-3
- 354 12. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review
355 of definitions. *BMC Geriatr.* 2017;17(1):230. doi:10.1186/s12877-017-0621-2
- 356 13. Remelli F, Ceresini MG, Trevisan C, Noale M, Volpato S. Prevalence and impact of polypharmacy
357 in older patients with type 2 diabetes. *Aging Clin Exp Res.* 2022;34(9):1969-1983.
358 doi:10.1007/s40520-022-02165-1
- 359 14. Rochon PA, Petrovic M, Cherubini A, et al. Polypharmacy, inappropriate prescribing, and
360 deprescribing in older people: through a sex and gender lens. *The Lancet Healthy Longevity.*
361 2021;2(5):e290-e300. doi:10.1016/S2666-7568(21)00054-4
- 362 15. Bhagavathula AS, Vidyasagar K, Chhabra M, et al. Prevalence of Polypharmacy,
363 Hyperpolypharmacy and Potentially Inappropriate Medication Use in Older Adults in India: A
364 Systematic Review and Meta-Analysis. *Frontiers in Pharmacology.* 2021;12. Accessed August 11,
365 2023. <https://www.frontiersin.org/articles/10.3389/fphar.2021.685518>
- 366 16. McKeigue PM, Kennedy S, Weir A, et al. Relation of severe COVID-19 to polypharmacy and
367 prescribing of psychotropic drugs: the REACT-SCOT case-control study. *BMC Medicine.*
368 2021;19(1):51. doi:10.1186/s12916-021-01907-8
- 369 17. Iloanusi S, Mgbere O, Essien EJ. Polypharmacy among COVID-19 patients: A systematic review. *J*
370 *Am Pharm Assoc (2003).* 2021;61(5):e14-e25. doi:10.1016/j.japh.2021.05.006
- 371 18. Rahman S, Singh K, Dhingra S, et al. The Double Burden of the COVID-19 Pandemic and
372 Polypharmacy on Geriatric Population – Public Health Implications. *Ther Clin Risk Manag.*
373 2020;16:1007-1022. doi:10.2147/TCRM.S272908
- 374 19. Madhavan S, Bastarache L, Brown JS, et al. Use of electronic health records to support a public
375 health response to the COVID-19 pandemic in the United States: a perspective from 15
376 academic medical centers. *J Am Med Inform Assoc.* 2021;28(2):393-401.
377 doi:10.1093/jamia/ocaa287
- 378 20. Casey JA, Schwartz BS, Stewart WF, Adler NE. Using Electronic Health Records for Population
379 Health Research: A Review of Methods and Applications. *Annual Review of Public Health.*
380 2016;37(1):61-81. doi:10.1146/annurev-publhealth-032315-021353
- 381 21. Kruse CS, Stein A, Thomas H, Kaur H. The use of Electronic Health Records to Support Population
382 Health: A Systematic Review of the Literature. *J Med Syst.* 2018;42(11):214.
383 doi:10.1007/s10916-018-1075-6
- 384 22. Cowie MR, Blomster JI, Curtis LH, et al. Electronic health records to facilitate clinical research.
385 *Clin Res Cardiol.* 2017;106(1):1-9. doi:10.1007/s00392-016-1025-6
- 386 23. Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using observational
387 routinely collected health data statement for pharmacoepidemiology (RECORD-PE). *BMJ.*
388 Published online November 14, 2018;k3532. doi:10.1136/bmj.k3532

- 389 24. Rahman S, Singh K, Dhingra S, et al. The Double Burden of the COVID-19 Pandemic and
390 Polypharmacy on Geriatric Population – Public Health Implications. *Ther Clin Risk Manag.*
391 2020;16:1007-1022. doi:10.2147/TCRM.S272908
- 392 25. Kerr L. Polypharmacy in diabetes and solutions for greater adherence. *Practical Diabetes*
393 *International.* 2009;26(7):289-290i. doi:10.1002/pdi.1402
- 394 26. The AHSN Network. Polypharmacy. The AHSN Network. Published 2022. Accessed April 7, 2023.
395 <https://www.ahsnnetwork.com/programmes/medicines/polypharmacy/>
- 396 27. Department of Health and Social Care. National overprescribing review report. GOV.UK.
397 Published 2023. Accessed April 7, 2023. [https://www.gov.uk/government/publications/national-](https://www.gov.uk/government/publications/national-overprescribing-review-report)
398 [overprescribing-review-report](https://www.gov.uk/government/publications/national-overprescribing-review-report)
- 399 28. Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged
400 and older adults and its association with multimorbidity and mortality: a prospective analysis of
401 493 737 UK Biobank participants. *The Lancet Public Health.* 2018;3(7):e323-e332.
402 doi:10.1016/S2468-2667(18)30091-4
- 403 29. Marzec LN, Maddox TM. Medication Adherence in Patients with Diabetes and Dyslipidemia:
404 Associated Factors and Strategies for Improvement. *Curr Cardiol Rep.* 2013;15(11):418.
405 doi:10.1007/s11886-013-0418-7
- 406 30. Carayon P, Du S, Brown R, Cartmill R, Johnson M, Wetterneck TB. EHR-related medication errors
407 in two ICUs. *J Healthc Risk Manag.* 2017;36(3):6-15. doi:10.1002/jhrm.21259
- 408 31. Gupta JK, Ravindrarajah R, Tilston G, Ollier W, Ashcroft DM, Heald AH. (2023). Association of
409 polypharmacy and burden of comorbidities on COVID-19 adverse outcomes in people with type 1 or
410 type 2 diabetes. *MedRxiv.* <https://www.medrxiv.org/content/10.1101/2023.08.12.23294016v1.full>
- 411